GW's Imitrex Approved In USA
Glaxo Wellcome has received approval from the US Food and DrugAdministration to market its nasal spray formulation of the 5-HT1 agonist Imitrex (sumatriptan) for the acute treatment of migraine with or without aura in adults. An approvable letter was received for the product in April.
The approval will open up the market for GW, which saw worldwide Imitrex/ Imigran (tablet and injection formulations) sales of L539 million ($857.8 million) in 1996. At a meeting for analysts earlier in the year, GW said that it expected the latest approval would grow the market.
The nasal spray has a rapid onset of action of 15 minutes (compared to 30 minutes for tablets and five-10 minutes for the injection). It is also convenient for patients who suffer with nausea and vomiting during their migraine, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze